Recombinant PTH analogs are indicated in severe chronic hypoparathyroidism with inadequate control of calcaemia, in spite of therapy with high doses of calcium (>2.5 g a day) and calcitriol (>1.5 micrograms a day), development of hypercalciuria, urinary stone disease, nephrocalcinosis, reduction of glomerular filtrate, hyperphosphatemia, gastrointestinal disorders associated with absorption, reduced quality of life. The gene discussed is PTH; the disease is nephrocalcinosis.